ANDREW TIMPSON
@Silverarc Capital Management, Llc
Latest period2024 - Q3ReportedManaged Assets$445.291MTotal holdings69
Assets growth rate5.06%Assets growth rate (2-Q avg)11.39%Continuous growth in asset value6 quarters
Portfolio positions
This chart displays the top 10 holdings in Silverarc Capital Management, Llc's 2024 - Q3 portfolio, based on their 13F SEC filing, out of a total of 69 positions.
Assets under management
The assets under management (AUM) of Silverarc Capital Management, Llc over the past 10 years (40 quarters) show continuous growth in total asset value over the last 6 quarters. As of the latest 13F SEC filing for 2024 - Q3, they manage 445.291M in assets, with a quarterly growth rate of 5.06% and a 2-quarter average growth rate of 11.39%. The portfolio is managed by ANDREW TIMPSON, and others.
Portfolio holdings
Investment | Portfolio % | Reported Value | Recent Activity |
---|---|---|---|
NUVLNuvalent Inc
| 8.54% | $37.998M 371,441 shares@ $102.3 avg price | Decreased -20.24% |
RNAAvidity Biosciences Inc
| 4.91% | $21.842M 475,555 shares@ $45.93 avg price | Decreased -8.14% |
ERASErasca Inc
| 4.26% | $18.964M 6.946M shares@ $2.73 avg price | Decreased -11.13% |
ITCIIntra-cellular Therapies Inc
| 2.75% | $12.227M 167,110 shares@ $73.18 avg price | Decreased -13.11% |
URGNUrogen Pharma Ltd
| 2.58% | $11.444M 901,129 shares@ $12.7 avg price | Decreased -18.22% |
ALNYAlnylam Pharmaceuticals Inc
| 2.21% | $9.839M 35,774 shares@ $275.03 avg price | Decreased -0.62% |
CCCCC4 Therapeutics Inc
| 1.67% | $7.398M 1.298M shares@ $5.71 avg price | Decreased -10.04% |
OLMAOlema Pharmaceuticals Inc
| 1.23% | $5.434M 455,082 shares@ $11.94 avg price | Decreased -16.78% |
BHVNBiohaven Ltd
| 1.12% | $4.975M 99,566 shares@ $49.97 avg price | Decreased -0.43% |
CLDXCelldex Therapeutics Inc New
| 1.11% | $4.929M 145,000 shares@ $33.99 avg price | Decreased -61.32% |